CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 8 enrolled
Drug / intervention
CI-581adrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02946489
NCT02946489Phase 1Completed
CompareCT.gov

Facilitating the Behavioral Treatment of Cannabis Use Disorder

New York State Psychiatric Institute·interventional·Posted Oct 27, 2016·Updated Feb 11, 2020

In Brief

A Phase 1 clinical trial evaluating CI-581a for Cannabis Dependence. Completed, enrolled 8 participants across 1 site.

Detailed Summary

Cannabis use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered cannabis use. Cannabis use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this single blind open-label trial is to test the feasibility of administering glutamate modulators in conjunction with motivational enhancement therapy (MET) and mindfulness based relapse prevention (MBRP) for cannabis use disorders.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 27, 2016
Enrollment StartOct 1, 2016
Primary CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.7 years ago

Interventions

CI-581adrug

CI-581a will be administered in wk2 and potentially in wk 3 or 4.